Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Tumour volume as a predictor of postoperative speech impairment in children undergoing resection of posterior fossa tumours: a prospective, multicentre study

AF. Laustsen, S. Avula, J. Grønbæk, B. Pizer, P. Nyman, P. Nilsson, R. Frič, MA. Hjort, V. Beneš, P. Hauser, B. Pálmafy, G. Rutkauskiene, F. Wilhelmy, R. Brandsma, A. Sehested, R. Mathiasen, M. Juhler

. 2025 ; 167 (1) : 97. [pub] 20250403

Language English Country Austria

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc25016176

BACKGROUND: Cerebellar Mutism Syndrome (CMS) is a neurological complication of posterior fossa (PF) tumour surgery in children, and postoperative speech impairment (POSI) is the cardinal symptom of CMS. The role of tumour volume on the risk of POSI remains unexplored. This study investigates the association between tumour volume and the risk of POSI. METHODS: We included 360 patients from the European CMS study with available preoperative T1-weighted contrast-enhanced brain MRI. Speech status was assessed within two weeks postoperatively and categorised into three levels: habitual speech, severely reduced speech, and mutism. Tumour volumes were calculated using the BrainLab Elements SmartBrushTM, a semi-automated segmentation tool. We used proportional odds models to estimate the odds ratio (OR) with adjustments for tumour location, pathology, and age. Based on the primary analysis, a risk stratification model for medulloblastoma patients was constructed, and the optimal volume cut-off was determined with Youden's Index. RESULTS: We found no effect of the overall tumour volume on the risk of POSI. This result did not change when adjusted for tumour location, pathology, and age. We found an association between tumour volume of medulloblastoma and the risk of POSI (unadjusted OR of 1.04 per increase in cm3 (95% CI 1.01;1.07, p = 0.01)), which did not change when adjusting for tumour location and age. The risk stratification cut-off for the tumour volume of medulloblastoma was calculated to be 16,5 cm3. Patients with medulloblastoma and preoperative tumour volumes below 16,5 cm3 had an absolute risk of 13% for POSI (low-risk group), whereas patients with preoperative tumour volumes above 16,5 cm3 had an absolute risk of 50% for POSI (high-risk group). CONCLUSION: Our data showed an association between preoperative tumour volume and the risk of POSI in children with medulloblastoma, while no association was found for the volume of other tumour types. We suggest a straightforward cut-off risk model for assessing the risk of POSI in children with medulloblastoma based on preoperative tumour volume. This approach can aid clinicians in informing patients and parents about the complications related to CMS following PF tumour surgery in children. CLINICAL TRIALS: ID NCT02300766 (October 2014).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016176
003      
CZ-PrNML
005      
20250731091552.0
007      
ta
008      
250708s2025 au f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00701-025-06459-x $2 doi
035    __
$a (PubMed)40178678
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a au
100    1_
$a Laustsen, Aske Foldbjerg $u Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark. aske.foldbjerg.laustsen@regionh.dk $u Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark. aske.foldbjerg.laustsen@regionh.dk $1 https://orcid.org/0000000235521346
245    10
$a Tumour volume as a predictor of postoperative speech impairment in children undergoing resection of posterior fossa tumours: a prospective, multicentre study / $c AF. Laustsen, S. Avula, J. Grønbæk, B. Pizer, P. Nyman, P. Nilsson, R. Frič, MA. Hjort, V. Beneš, P. Hauser, B. Pálmafy, G. Rutkauskiene, F. Wilhelmy, R. Brandsma, A. Sehested, R. Mathiasen, M. Juhler
520    9_
$a BACKGROUND: Cerebellar Mutism Syndrome (CMS) is a neurological complication of posterior fossa (PF) tumour surgery in children, and postoperative speech impairment (POSI) is the cardinal symptom of CMS. The role of tumour volume on the risk of POSI remains unexplored. This study investigates the association between tumour volume and the risk of POSI. METHODS: We included 360 patients from the European CMS study with available preoperative T1-weighted contrast-enhanced brain MRI. Speech status was assessed within two weeks postoperatively and categorised into three levels: habitual speech, severely reduced speech, and mutism. Tumour volumes were calculated using the BrainLab Elements SmartBrushTM, a semi-automated segmentation tool. We used proportional odds models to estimate the odds ratio (OR) with adjustments for tumour location, pathology, and age. Based on the primary analysis, a risk stratification model for medulloblastoma patients was constructed, and the optimal volume cut-off was determined with Youden's Index. RESULTS: We found no effect of the overall tumour volume on the risk of POSI. This result did not change when adjusted for tumour location, pathology, and age. We found an association between tumour volume of medulloblastoma and the risk of POSI (unadjusted OR of 1.04 per increase in cm3 (95% CI 1.01;1.07, p = 0.01)), which did not change when adjusting for tumour location and age. The risk stratification cut-off for the tumour volume of medulloblastoma was calculated to be 16,5 cm3. Patients with medulloblastoma and preoperative tumour volumes below 16,5 cm3 had an absolute risk of 13% for POSI (low-risk group), whereas patients with preoperative tumour volumes above 16,5 cm3 had an absolute risk of 50% for POSI (high-risk group). CONCLUSION: Our data showed an association between preoperative tumour volume and the risk of POSI in children with medulloblastoma, while no association was found for the volume of other tumour types. We suggest a straightforward cut-off risk model for assessing the risk of POSI in children with medulloblastoma based on preoperative tumour volume. This approach can aid clinicians in informing patients and parents about the complications related to CMS following PF tumour surgery in children. CLINICAL TRIALS: ID NCT02300766 (October 2014).
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dítě $7 D002648
650    12
$a infratentoriální nádory $x chirurgie $x patologie $7 D015192
650    12
$a pooperační komplikace $x etiologie $7 D011183
650    _2
$a předškolní dítě $7 D002675
650    12
$a meduloblastom $x chirurgie $x patologie $7 D008527
650    _2
$a prospektivní studie $7 D011446
650    _2
$a mladiství $7 D000293
650    12
$a tumor burden $7 D047368
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    12
$a poruchy řeči $x etiologie $7 D013064
650    12
$a mutismus $x etiologie $7 D009155
650    12
$a nádory mozečku $x chirurgie $x patologie $7 D002528
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Avula, Shivaram $u Department of Radiology, Alder Hey Children'S NHS Foundation, Liverpool, UK $1 https://orcid.org/0000000317427206
700    1_
$a Grønbæk, Jonathan $u Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark $u Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark $1 https://orcid.org/000000027170422X
700    1_
$a Pizer, Barry $u University of Liverpool, Liverpool, L69 3BX, UK $1 https://orcid.org/0000000349456386
700    1_
$a Nyman, Per $u Crown Princess Victoria Children'S Hospital and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden $1 https://orcid.org/000000018921431X
700    1_
$a Nilsson, Pelle $u Department of Medical Sciences/Neurosurgery, Uppsala University, Uppsala University Hospital, Uppsala, Sweden
700    1_
$a Frič, Radek $u Department of Neurosurgery, University Hospital Oslo, Oslo, Norway $1 https://orcid.org/0000000242670542
700    1_
$a Hjort, Magnus Aasved $u Department of Pediatric Hematology and Oncology, St Olavs Hospital, Trondheim, Norway $1 https://orcid.org/0000000294553110
700    1_
$a Beneš, Vladimír $u Department of Neurosurgery, 2nd Medical Faculty and Motol University Hospital, Prague, Czechia $1 https://orcid.org/000000026889857X $7 jn20000400135
700    1_
$a Hauser, Peter $u 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000283078975
700    1_
$a Pálmafy, Beatrix $u National Institute of Neuroscience, Budapest, Hungary
700    1_
$a Rutkauskiene, Giedre $u Department of Pediatrics, Lithuanian University of Health Science, Kaunas, Lithuania $1 https://orcid.org/0009000854807914
700    1_
$a Wilhelmy, Florian $u Department of Neurosurgery, University Hospital Leipzig, Leipzig, Germany $1 https://orcid.org/000000021304346X
700    1_
$a Brandsma, Rick $u Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands $1 https://orcid.org/0000000271662242
700    1_
$a Sehested, Astrid $u Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark $1 https://orcid.org/0009000444503539
700    1_
$a Mathiasen, René $u Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark $1 https://orcid.org/0000000337827776
700    1_
$a Juhler, Marianne $u Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark $1 https://orcid.org/0000000326527495
773    0_
$w MED00009022 $t Acta neurochirurgica $x 0942-0940 $g Roč. 167, č. 1 (2025), s. 97
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40178678 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091547 $b ABA008
999    __
$a ok $b bmc $g 2366778 $s 1253301
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 167 $c 1 $d 97 $e 20250403 $i 0942-0940 $m Acta neurochirurgica $n Acta Neurochir (Wien) $x MED00009022
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options